Analysts think VTYX stock price could increase by 371%
Dec 28, 2024, 12:26 PM
-5.67%
What does VTYX do
Ventyx Biosciences, a San Diego-based clinical-stage biopharmaceutical company, develops small molecule therapeutics for autoimmune diseases with a pipeline including VTX002, VTX958, VTX2735, and VTX3232. The company went public on October 21, 2021, and employs 74 people.
9 analysts think VTYX stock price will increase by 371.43%. The current median analyst target is $11.22 compared to a current stock price of $2.38. The lowest analysts target is $2.02 and the highest analyst target is $22.05.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
